# Kasvu Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kasvu-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Helsinki, Finland
- Website: www.kasvutx.com
- Total disclosed funding: $34M
- Latest round: Series A (Sep 24, 2026)
- Investors on record: 7

## About

Based in Helsinki, Finland and founded in 2023 by Jami Mandelin (co-founder and CEO), Eero Castrén (co-founder) and Ilpo Vattulainen (co-founder), Kasvu Therapeutics is a drug-development company developing small-molecule TrkB positive allosteric modulators for neuropsychiatric and neurodegenerative disorders. Its lead programme, KTX-0141, is being advanced for major depressive disorder and is designed to enhance neuroplasticity without engaging the 5-HT2A receptor responsible for the hallucinogenic effects of psychedelics. In September 2026, Kasvu Therapeutics raised EUR 30 million in series A funding led by Hadean Ventures, with participation from Tesi, Finnish Drug Discovery Center, Nordic Science Investments, Stephen Industries, Innovestor, Helsinki University Funds.
The company will use the September 2026 funding to support its drug research, manufacturing, and advance it clinical trials for major depressive disorder.

## Funding rounds

- Series A, Sep 24, 2026, $34M — Tesi, Helsinki University Funds, Hadean Ventures, Innovestor, Stephen Industries, Nordic Science Investments, Finnish Drug Discovery Center

## Investors

- Tesi (https://capitalatlas.ai/funds/tesi) — Series A
- Helsinki University Funds — Series A
- Hadean Ventures (https://capitalatlas.ai/funds/hadean-ventures) — Series A
- Innovestor (https://capitalatlas.ai/funds/innovestor) — Series A
- Stephen Industries — Series A
- Nordic Science Investments (https://capitalatlas.ai/funds/nordic-science-investments) — Series A
- Finnish Drug Discovery Center — Series A